ZYN002 - Cannabidiol Transdermal Gel

DRUG2 trials

Sponsors

Zynerba Pharmaceuticals, Inc.

Conditions

Fragile X Syndrome

Phase 2

Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)

CompletedNCT03614663

Zynerba Pharmaceuticals, Inc.Fragile X Syndrome

Start: 2018-06-12End: 2020-06-14Updated: 2022-07-06

Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

Enrolling by invitationNCT03802799

Zynerba Pharmaceuticals, Inc.Fragile X Syndrome

Start: 2018-11-09End: 2027-08-31Target: 550Updated: 2025-11-05

Related Papers

Caregiver-perceived behavioral challenges in fragile X syndrome and implications for measuring treatment benefit in clinical trials

Journal of Patient-Reported Outcomes2026-04-01

Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study.

2025-11-18

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Journal of Neurodevelopmental Disorders2022-11-2560 citations

Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial

BMJ Open2020-03-0116 citations